Nama's AI scorecard currently rates Teva Pharmaceutical Industries Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TEVA's P/E ratio?

Teva Pharmaceutical Industries trades at a trailing price-to-earnings ratio of 18.0.

When does TEVA report earnings?

Teva Pharmaceutical Industries's next scheduled report is on Jan 27, 2027. Analysts expect EPS of $0.70.

What is the TEVA price target?

The median analyst price target from 14 analysts is $48.50, with a range of $42.00 – $57.00.

Is TEVA Shariah compliant?

Nama's AAOIFI-style screen reads Teva Pharmaceutical Industries as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Teva Pharmaceutical Industries (TEVA)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Teva Pharmaceutical Industries (TEVA) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $49.72B, a trailing price-to-earnings ratio of 18.0 and a free-cash-flow yield of 2.3%. Over the most recent reported fiscal year, revenue grew 4.3% and free cash flow per share grew 49.0%. Nama's AI scorecard rates it Hold, 4.5 out of 10.

AI scorecard

Hold · 4.5/10

The sections balance. As of Nov 7, 2026.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-1.7%

How far the last close sits under the highest price of the past five years.

Market cap	$49.72B
Trailing P/E	18.0
Price / book	6.4
Price / sales	2.9
FCF yield	2.3%
Dividend yield	—
Gross margin	52.5%
Operating margin	18.8%
Net margin	4.1%
Revenue growth (YoY)	+4.3%
Revenue growth (3-yr annual)	+5.0%
EPS growth (YoY)	+17.3%
FCF/share growth (YoY)	+49.0%
Beta	0.8
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

TEVA earnings

Next report: Jan 27, 2027 (Q4 2026, EPS estimate $0.70). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.86	$0.72	+19.4%	$4.39B
Q2 2026	Jul 29, 2026	$0.02	$0.11	-81.8%	$4.14B
Q1 2026	Apr 29, 2026	$0.53	$0.46	+15.2%	$3.98B
Q4 2025	Jan 28, 2026	$0.96	$0.64	+50.0%	$4.71B

TEVA analyst price target

Median target $48.50 from 14 analysts, ranging $42.00 – $57.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3
RDY	Dr. Reddy's Laboratories	$12.43B	20.4

Explore live TEVA data on Nama Insights →

Recent Congressional trades

Teva Pharmaceutical Industries trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Patty Murray	Senate	Sell	$1,001 - $15,000	—
Angus S King, Jr.	Senate	Sell	$1,001 - $15,000	—

TEVA FAQ

Is TEVA a buy?: Nama's AI scorecard currently rates Teva Pharmaceutical Industries Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TEVA's P/E ratio?: Teva Pharmaceutical Industries trades at a trailing price-to-earnings ratio of 18.0.
When does TEVA report earnings?: Teva Pharmaceutical Industries's next scheduled report is on Jan 27, 2027. Analysts expect EPS of $0.70.
What is the TEVA price target?: The median analyst price target from 14 analysts is $48.50, with a range of $42.00 – $57.00.
Is TEVA Shariah compliant?: Nama's AAOIFI-style screen reads Teva Pharmaceutical Industries as Not Shariah Compliant. At least one of the three ratios or the industry test failed.